Pembrolizumab plus chemo shows benefits for PD-L1–rich triple-negative breast cancerMay 29, 2020Breast CancerMetastatic Breast Cancer
LOTUS: Ipatasertib plus paclitaxel may prolong OS in TNBCMay 28, 2020Breast CancerMetastatic Breast Cancer
Mammography cuts risk for fatal breast cancers: New dataMay 13, 2020Breast CancerMetastatic Breast Cancer
Novel immune activator boosts immunotherapy benefit in TNBCMay 1, 2020Breast CancerMetastatic Breast Cancer
EMBRACA shows no overall survival benefit with talazoparibApril 29, 2020Breast CancerMetastatic Breast Cancer
Metastatic cancer linked to worse outcomes of COVID-19April 29, 2020Breast CancerMetastatic Breast Cancer
ESMO gets creative with guidelines for breast cancer care in the COVID-19 eraApril 28, 2020Breast CancerMetastatic Breast Cancer
FDA OKs new drug for triple-negative breast cancerApril 23, 2020Breast CancerMetastatic Breast Cancer
FDA approves first new breast cancer drug with international groupApril 20, 2020Breast CancerMetastatic Breast Cancer
Breast-conserving surgery deemed okay in high-risk hereditary breast cancersApril 15, 2020Breast CancerMetastatic Breast Cancer
When to treat, delay, or omit breast cancer therapy in the face of COVID-19April 10, 2020Breast CancerMetastatic Breast Cancer
CLEOPATRA: Pertuzumab has long-term benefit in HER2+ breast cancerMarch 27, 2020Breast CancerMetastatic Breast Cancer
HRQOL deteriorates after disease progression in metastatic cancerMarch 11, 2020Breast CancerMetastatic Breast Cancer
FDA approves neratinib in combination for metastatic HER2-positive breast cancerFebruary 27, 2020Breast CancerMetastatic Breast Cancer
Metastatic breast cancer lesions immunologically depleted compared with primarySeptember 17, 2018Breast CancerMetastatic Breast Cancer
